Skip to content

PRIMA Biobank

PRIMA Biobank: Identifying novel targeted therapies for genetic & degenerative aneurysms in-vitro - PRIMA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57907
Enrollment
1000
Registered
2025-07-13
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysm

Interventions

No product under research or intervention. The study concerns a biobank.&nbsp

Sponsors

Maastricht Universitair Medisch Centrum +
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with an arterial aneurysm (thoracic aortic aneurysm/abdominal aortic aneurysm/intracranial aneurysm). 

Exclusion criteria

Exclusion criteria: Mentally incapacitated patients, patients < 18 years old  

Design outcomes

Primary

MeasureTime frame
Given the exploratory and long-term nature of this biobank, specific outcome measures will depend on the individual research questions addressed in future studies. However, the biobank is designed to support a wide range of potential outcome measures across various domains, including: Biological and molecular outcomes: Identification of biomarkers (e.g., proteins, gene variants, RNA expression patterns) associated with aneurysm presence, growth, or rupture risk.Genetic outcomes: Associations between genetic variants and aneurysm subtypes, progression, or familial predisposition (e.g., via genome-wide association studies or sequencing approaches).Clinical outcomes: Correlations between clinical characteristics (e.g., age, sex, comorbidities, medication use) and aneurysm progression or treatment response.Imaging or anatomical outcomes: Aneurysm size, growth rate, morphology, or rupture incidence over time.Therapeutic outcomes (translational research): Response to candidate drug targets in ex vivo models, or identification of mechanisms underlying treatment resistance or efficacy.

Countries

Netherlands

Contacts

Public ContactBME Mees

Maastricht Universitair Medisch Centrum +

linda.lemmens@mumc.nl+3143377478

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)